SARS-CoV-2 Inhibitor Screening Kit

COVID-19 Inhibitor Screening Kit; 2019-nCoV Inhibitor Screening Kit; 2019-nCoV Spike Protein S1 (RBD)/ACE2 Inhibitor Screening Kit

Colorimetric

32160000

After standard reconstitution, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Plate and reagents should reach room temperature before use.

1 vial ACE2 (human)(rec.) (Biotin) (lyophilized) ----- 10 µg 1 vial SARS-CoV-2 Spike S (RBD):Fc (h) (rec.) (lyophilized) ----- 10 µg 1 vial HRP Labeled Streptavidin (lyophilized) ----- 2 µg 1 vial ACE2 (h), mAb (blocking) (AC384) (rec.) ----- 20 µl 1 vial anti-human IgG (HRP) ----- 120 µl 1 MaxiSorp™flat-bottom 96 well plate ----- 6x16-well strips 2 bottles Wash Buffer 10x ----- 2 x 30 ml 1 bottle ELISA Buffer 10x ----- 30 ml 1 bottle Blocking Buffer ----- 24 ml 1 bottle TMB K-Blue Aqueous ----- 12 ml 1 bottle Stop Solution ----- 12 ml 2 silica gel minibags 2 plate sealers (plastic film)

Screening Assay: To screen compounds that inhibit the binding of the viral protein SARS-CoV-2 Spike Protein (RBD) to its human receptor ACE2. Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells. The SARS-CoV-2 Inhibitor Screening Kit contains key reagents required to facilitate identification of SARS-CoV-2 inhibitors. This inhibitor screen is based on a colorimetric ELISA kit, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 to its human receptor ACE2. This assay allows to identify and characterize the effect of different inhibitory molecules including antibodies or chemicals on the prevention of binding of SARS-CoV-2 virus to any ACE2-expressing cells.

Plastic Vial

Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells. The SARS-CoV-2 Inhibitor Screening Kit contains key reagents required to facilitate identification of SARS-CoV-2 inhibitors. This inhibitor screen is based on a colorimetric ELISA kit, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 to its human receptor ACE2. This assay allows to identify and characterize the effect of different inhibitory molecules including antibodies or chemicals on the prevention of binding of SARS-CoV-2 virus to any ACE2-expressing cells.

To screen compounds that inhibit the binding of the viral protein SARS-CoV-2 Spike Protein (RBD) to its human receptor ACE2.

Non-hazardous

General Purpose Cell Biology Kits

41116111

12 months after the day of manufacturing. See expiry date on ELISA Kit box.